TheraRadar
← Back
Data updated: Jun 28, 2026

ZENARA

Generics

ZENARA is a generic drug manufacturer focused on Oncology, Gastroenterology, Neurology.

2025
Since
6
Drugs
-
Trials
0
New Drugs (2yr)

ZENARA's Key Drugs

ZENARA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ZENARA's Recent FDA Approvals

New NDA/BLA approvals for ZENARA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ZENARA's Therapeutic Areas

ZENARA's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 33%
1 drugs
Gastroenterology 33%
1 drugs
Neurology 33%
1 drugs

ZENARA's Top Competitors

ZENARA's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and EMD SERONO. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ZENARA Pipeline Snapshot

Active clinical trials for ZENARA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling